SWOG clinical trial number
CTSU/A071401

Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations

Open
Phase
Abbreviated Title
Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas
Status Notes
Activated by Alliance: 8/28/2015
Activated by SWOG: 1/1/2016

NF2 Grade I and NF2 Grade II/III Cohorts permanently closed to accrual, Effective 7/19/17.

SMO/PTCH1 Grade I and SMO/PTCH1 Grade II/III cohorts temporarily closed to accrual on 2/7/18, since the manufacturer of vismodegib discontinued provision to new patients on A071401.
Activated
01/01/2016

Research committees

Early Therapeutics & Rare Cancers

Treatment

Vismodegib GSK2256098 Afuresertib

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2022

Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations

P Brastianos;E Twohy;E Gerstner;T Kaufmann;A Iafrate;S Jeyapalan;D Piccioni;V Monga;A Lassman;C Fadul;D Schiff;J Taylor;S Chowdhary;C Bettegowda;G Ansstas;F Lieberman;M De La Fuente;R Peterson;S Anderson;M Anderson;N Shonka;D Damek;L Kunschner-Ronan;R Chaurhary;M O'Rourke;F Senecal;J Carrillo;T Kaley;T Morrison;A Thomas;M Welch;F Iwamoto;D Cachia;A Cohen;S Vora;M Knopp;I Dunn;P Kumthekar;J Sarkaria;S Geyer;X Carrero;M Martinez-Lage;D Cahill;P Brown;C Giannini;S Santagata;F Barker;E Galanis Journal of Clinical Oncology Oct 26;JCO2102371. doi: 10.1200/JCO.21.02371. Online ahead of print.

PMid: PMID36288512

Other Clinical Trials

SWOG Clinical Trial Number
SN2426

A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Sarcoma
Activated
01/28/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/AOST2032

AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/17/2023
Open
SWOG Clinical Trial Number
CTSU/AOST2031

AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/15/2022
Open